Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma.
Date
2013Author
Ansari, J
Hussain, SA
Ansari, A
Glaholm, J
Subject
clear-cell carcinoma metastatic RCC molecular targeted agent vascular endothelial growth factor receptor inhibitor
Metadata
Show full item recordAbstract
A growing understanding of the biology of renal cell carcinoma (RCC) has led to the development and US Food and Drug Administration approval of seven new molecular targeted agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular endothelial growth factor receptors and the latest to join the armamentarium of drugs available for the treatment of metastatic RCC. Despite recent advances in the development of molecular targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.
Collections
Place of Publication
New Zealand
Journal
Biologics
Volume
7
Pagination
39 - 46
Author URL
Recommended, similar items
The following license files are associated with this item: